- Conditions
- Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus
- Interventions
- blood donation
- Procedure
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 11,398
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Persistent Allergic Asthma
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 50
- States / cities
- Jasper, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- Tadalafil, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 7 Years to 14 Years · Male only
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 20 more
- Conditions
- Advanced/Metastatic Solid Tumor
- Interventions
- KZR-261
- Drug
- Lead sponsor
- Kezar Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more
- Conditions
- Hereditary Diseases, Critical Illness
- Interventions
- Genome sequencing
- Genetic
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Tuberous Sclerosis Complex
- Interventions
- Ganaxolone, Placebo
- Drug
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- MGD007 + MGA012
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 3 more
- Conditions
- Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- management of therapy complications
- Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more
- Conditions
- Non-Alcoholic Steatohepatitis (NASH)
- Interventions
- SEL, SIM
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 26
- States / cities
- Palo Alto, California • San Diego, California • San Francisco, California + 21 more
- Conditions
- Steroid-Refractory Acute Graft Versus Host Disease
- Interventions
- T-Guard
- Drug
- Lead sponsor
- Xenikos
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 24
- States / cities
- Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 20 more
- Conditions
- Multiple Myeloma, Plasma Cell Myeloma, Precancerous Condition
- Interventions
- cytogenetic analysis, microarray analysis, biologic sample preservation procedure, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 41 more
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Presatovir, Presatovir placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Annapolis, Maryland • Detroit, Michigan + 6 more
- Conditions
- Tumors Characterized by Genetic Abnormalities of ALK
- Interventions
- LDK378
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
- Conditions
- Acquired Bleeding Disorder, Intracerebral Haemorrhage
- Interventions
- eptacog alfa (activated)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 829 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Alzheimer Disease, Dementia
- Interventions
- Heavy Cream
- Dietary Supplement
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Herpes Simplex
- Interventions
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 505 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more
- Conditions
- Multiple Sclerosis
- Interventions
- RPC-1063
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 49 more
- Conditions
- Antibody-mediated Rejection
- Interventions
- Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more
- Conditions
- HIV Pre-exposure Prophylaxis
- Interventions
- Lenacapavir Injection, Lenacapavir Tablet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 339 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 21 more
- Conditions
- HIV-1 Infection
- Interventions
- depo-medroxyprogesterone acetate
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 13 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 7 more
- Conditions
- Autism Spectrum Disorder, Neurodevelopmental Disorders
- Interventions
- Remaking Recess (RR)
- Behavioral
- Lead sponsor
- Health Resources and Services Administration (HRSA)
- Federal
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Rochester, New York • Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Pregnancy, Effective Contraceptive Use, Family Planning
- Interventions
- Enhanced NFP Care
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 15 Years to 45 Years · Female only
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Olympia, Washington • Seattle, Washington • Vancouver, Washington
- Conditions
- Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Psychosocial Effects of Cancer and Its Treatment, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- educational intervention, counseling intervention, psychosocial support for caregiver
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Not listed
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Clostridium Difficile Infection
- Interventions
- SMT19969, Vancomycin
- Drug
- Lead sponsor
- Summit Therapeutics
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 24
- States / cities
- Mobile, Alabama • Laguna Hills, California • Long Beach, California + 21 more